BioCentury | Jul 21, 2017
Financial News

Nuo amends follow-on

...On June 30, wound care company Nuo Therapeutics Inc. (OTCQX:NUOT) amended its follow-on, increasing the amount raised to...
...to $10 million in a follow-on underwritten by Northland Capital Markets. Nuo Therapeutics Inc. (OTCQX:NUOT), Gaithersburg, Md. Mary Romeo Nuo Therapeutics Inc....
BioCentury | Apr 14, 2017
Financial News

Nuo proposes follow-on

...Wound care company Nuo Therapeutics Inc. (OTCQX:NUOT) proposed to raise up to $10 million on April 10 in...
...on April 10 in a follow-on underwritten by Northland Capital Markets. Nuo Therapeutics Inc. (OTCQX:NUOT), Gaithersburg, Md. Julian Zhu Nuo Therapeutics Inc....
BioCentury | Feb 1, 2016
Company News

Nuo Therapeutics dermatology news

...Nuo had about $4.1 million in cash and a nine-month operating loss of $35.1 million. Nuo Therapeutics Inc....
BioCentury | May 5, 2015
Company News

Management tracks

...Steven Shallcross CFO, treasurer, and secretary, effective June 1. Shallcross is EVP and CFO at Nuo Therapeutics Inc....
BioCentury | Apr 6, 2015
Clinical News

Aurix System: Phase IV started

...venous and/or pressure wounds. Rohto has exclusive rights in Japan to develop and commercialize Aurix. Nuo Therapeutics...
BioCentury | Oct 27, 2014
Company News

Nuo Therapeutics sales and marketing update

...Nuo Therapeutics (formerly Cytomedix Inc. ) re-launched its AutoloGel System in the U.S. under the Aurix...
...reimbursement for the product in 2014 is $409 per treatment (see BioCentury, March 11, 2013). Nuo Therapeutics Inc....
BioCentury | Jun 30, 2014
Financial News

Cytomedix completes private placement of senior convertible notes

...senior convertible notes Raised: $26 million Shares outstanding prior: 121.7 million Investor: Deerfield Management Note: Cytomedix...
BioCentury | May 26, 2014
Clinical News

ALD-401: Phase II data

...primary endpoint of improving mean mRS scores from baseline to day 90 vs. sham control. Cytomedix...
...Durham, N.C. Cytomedix expects the closure to save about $4 million per year. Last September, Cytomedix...
...2013, Cytomedix had $3.8 million in cash and a 12-month operating loss of $18.1 million. Cytomedix...
BioCentury | Apr 7, 2014
Company News

Cytomedix management update

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md. Business: Dermatology Hired: Dean Tozer as EVP and chief commercial officer, formerly VP of corporate development at the regenerative medicine unit of Shire plc WIR Staff Dermatology...
BioCentury | Apr 7, 2014
Financial News

Cytomedix completes private placement of senior convertible notes

...Raised: $9 million Placement agent: BTIG Shares outstanding prior: 114.6 million Investor: Deerfield Management Note: Cytomedix...
Items per page:
1 - 10 of 65
BioCentury | Jul 21, 2017
Financial News

Nuo amends follow-on

...On June 30, wound care company Nuo Therapeutics Inc. (OTCQX:NUOT) amended its follow-on, increasing the amount raised to...
...to $10 million in a follow-on underwritten by Northland Capital Markets. Nuo Therapeutics Inc. (OTCQX:NUOT), Gaithersburg, Md. Mary Romeo Nuo Therapeutics Inc....
BioCentury | Apr 14, 2017
Financial News

Nuo proposes follow-on

...Wound care company Nuo Therapeutics Inc. (OTCQX:NUOT) proposed to raise up to $10 million on April 10 in...
...on April 10 in a follow-on underwritten by Northland Capital Markets. Nuo Therapeutics Inc. (OTCQX:NUOT), Gaithersburg, Md. Julian Zhu Nuo Therapeutics Inc....
BioCentury | Feb 1, 2016
Company News

Nuo Therapeutics dermatology news

...Nuo had about $4.1 million in cash and a nine-month operating loss of $35.1 million. Nuo Therapeutics Inc....
BioCentury | May 5, 2015
Company News

Management tracks

...Steven Shallcross CFO, treasurer, and secretary, effective June 1. Shallcross is EVP and CFO at Nuo Therapeutics Inc....
BioCentury | Apr 6, 2015
Clinical News

Aurix System: Phase IV started

...venous and/or pressure wounds. Rohto has exclusive rights in Japan to develop and commercialize Aurix. Nuo Therapeutics...
BioCentury | Oct 27, 2014
Company News

Nuo Therapeutics sales and marketing update

...Nuo Therapeutics (formerly Cytomedix Inc. ) re-launched its AutoloGel System in the U.S. under the Aurix...
...reimbursement for the product in 2014 is $409 per treatment (see BioCentury, March 11, 2013). Nuo Therapeutics Inc....
BioCentury | Jun 30, 2014
Financial News

Cytomedix completes private placement of senior convertible notes

...senior convertible notes Raised: $26 million Shares outstanding prior: 121.7 million Investor: Deerfield Management Note: Cytomedix...
BioCentury | May 26, 2014
Clinical News

ALD-401: Phase II data

...primary endpoint of improving mean mRS scores from baseline to day 90 vs. sham control. Cytomedix...
...Durham, N.C. Cytomedix expects the closure to save about $4 million per year. Last September, Cytomedix...
...2013, Cytomedix had $3.8 million in cash and a 12-month operating loss of $18.1 million. Cytomedix...
BioCentury | Apr 7, 2014
Company News

Cytomedix management update

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md. Business: Dermatology Hired: Dean Tozer as EVP and chief commercial officer, formerly VP of corporate development at the regenerative medicine unit of Shire plc WIR Staff Dermatology...
BioCentury | Apr 7, 2014
Financial News

Cytomedix completes private placement of senior convertible notes

...Raised: $9 million Placement agent: BTIG Shares outstanding prior: 114.6 million Investor: Deerfield Management Note: Cytomedix...
Items per page:
1 - 10 of 65